Hemp Industry Daily reports

A panel of government health advisers gave a unanimous recommendation Thursday to the U.S. Food and Drug Administration to approve Epidiolex, a CBD medicine for rare epilepsy conditions that don’t respond to other drugs.

A final decision on rescheduling would be made by the U.S. Drug Enforcement Administration and the FDA’s parent agency, the U.S. Department of Health and Human Services.

The advisory panel’s 13-0 recommendation doesn’t bind the agency to approving Epidiolex, but its recommendations carry serious weight.

The FDA has said it will issue a decision by late June.

CBD epilepsy treatment wins unanimous approval from FDA advisers

The Marijuana Times report

CBD Medication Epidiolex Receives a Positive Review from the FDA

A quick Google share price search shows  what the decision means for the company and shareholders

1:35Pm Friday 20 April ( Sydney Australia Time)


Meanwhile in Colorado the battle lines are already being drawn.

Earlier in the week House Bill 18-1187 was presented and entitled


See our piece ….

GW Pharmaceuticals & Their Interests Preparing Ground In Colorado House For FDA Approval of Epidiolex with House Bill 18-1187


Amendments to HB 18-1187  are on the way and we will publish when they are public.


We have a feeling this one will run for a while and not just in Colorado.